Four patients with cholangiocarcinoma had SD; of whom one had a centrally confirmed FGF1 and FGFR2 amplification and one had a centrally confirmed FGFR2 rearrangement and locally identified FGFR2 translocation. Here, FGFR2 is linked to cholangiocarcinoma.